Misfolded Protein Biomarkers in blood and brain of cognitively normal individuals
Research type
Research Study
Full title
Quantification of beta-amyloid deposition as determined by PET and plasma biomarkers in cognitively normal individuals
IRAS ID
303826
Contact name
Eugenii Rabiner
Contact email
Sponsor organisation
Imanova Limited trading as Invicro
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Alzheimer Disease (AD) continues to be a significant public health challenge. Physicians continue to face challenges with both diagnosis and patient care management. The gold standard in AD diagnosis is a clinical examination supportd by a PET scan to measure brain levels of beta-amyloid, a protein involed in AD. PET scans are a medical imaging technique that is expensive and not available widely. To address this, blood tests are being developed to potentially replace the need for PET scans. This study will examine volunteers who are cognitively normal, and will collect PET and bklood data from them in order to assess the levels of the two biomarkers in a healthy population.
REC name
London - Stanmore Research Ethics Committee
REC reference
21/LO/0616
Date of REC Opinion
27 Sep 2021
REC opinion
Further Information Favourable Opinion